What is Pluri?
Pluri Inc. operates at the forefront of the biotechnology sector, utilizing a sophisticated, proprietary cell expansion platform to manufacture biological cells at scale. Unlike conventional methods, Pluri's technology enables the efficient production of cells for diverse applications, ranging from regenerative medicine to sustainable food solutions. By focusing on the scalability of cell-based manufacturing, the company addresses critical bottlenecks in the bio-economy, providing a robust infrastructure for partners and research institutions alike. Its market position is defined by its ability to bridge the gap between laboratory-scale innovation and industrial-grade production, making it a vital contributor to the future of synthetic biology and advanced therapeutics.
How much funding has Pluri raised?
Pluri has raised a total of $10M across 2 funding rounds:
Other Financing Round
$6.5M
Other Financing Round
$3.5M
Other Financing Round (2025): $6.5M, investors not publicly disclosed
Other Financing Round (2025): $3.5M led by Merchant Adventure Investment Advisors
Key Investors in Pluri
Merchant Adventure Investment Advisors
A global investment firm focused on knowledge-based companies that create new products and services delivering greater utility, with a specific interest in management competency and franchise quality.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Pluri?
With the successful closure of this major strategic investment, Pluri is expected to prioritize the expansion of its manufacturing capabilities and the deepening of its research partnerships. The company's roadmap likely involves scaling its cell expansion platforms to meet the growing demand for sustainable protein sources and advanced medical treatments. As Pluri transitions into this next phase of growth, the focus will remain on optimizing operational efficiency and securing regulatory milestones that validate its technology for broader commercial adoption. Investors will be closely monitoring the company's ability to translate its technical prowess into long-term, sustainable revenue streams within the competitive global biotechnology landscape.
See full Pluri company page
